The 2020 COMPPARE Workshop: Accrual, Monitoring, and Engagement, held in Amelia Island, FL, January 17 – 19, 2020, allowed researchers and patients to cross-pollinate their ideas and help COMPPARE succeed.
One important outcome of the meeting, the decision to expand COMPPARE eligibility criteria, was derived from the feedback of Principal Investigators who attended.
“Prostate cancer affects approximately 11% of all men, so it’s important for us to gather the data we need to aid in decisions regarding health insurance coverage – especially those that include the use of protons for prostate cancer more consistently,” said Nancy Mendenhall, MD, Principal Investigator, University of Florida Proton Therapy Institute. “It is our hope that more prostate patients will have the opportunity to enroll through the expansion of the eligibility criteria for COMPPARE.”
The following five changes to the study’s eligibility criteria have been implemented:
- The maximum age of participants has been increased, from 80 to 85.
- Life Expectancy Estimation (LEE) has been decreased, from ≥ 10 year to ≥ 8 year.
- Very low-risk patients are now included.
- Patients with prior Benign Prostatic Hyperplasia (BPH) procedures, such as TURP and GreenLight Laser, are now included.
- Inflammatory Bowel Disease (IBD) is now only an exclusion if a patient is undergoing active treatment or symptomatic.
For more information about COMPPARE, visit our Participant Information page, or email email@example.com.